Debio-0228 is under clinical development by Debiopharm International and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Debio-0228’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Debio-0228 overview

Debio-0228 is under development for the treatment of unresectable locally advanced or metastatic solid tumors including renal cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer and mesothelioma (malignant mesothelioma). The drug candidate comprises of PurAffin ligands which are chemically stabilized peptide ligands (peptidomimetics) coupled to a therapeutic radioisotope via a linker and radioconjugated to a chelator. The drug candidate is developed based on PurAffin technology. It is administered through intravenous route.

Debiopharm International overview

Debiopharm International, a subsidiary of Apes-demain SA focuses on the development and manufacture of drugs for oncology and bacterial infections. it offers complete treatment to the patients from diagnostics to treatment monitoring. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.

For a complete picture of Debio-0228’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.